* Aquila Biopharmaceuticals Inc., of Worcester, Mass., has received a patent covering various aspects of the company's proprietary adjuvant technology. The patent covers chemical modifications to Stimulon adjuvants, including QS-21 and contains claims to an alternative method for producing products through chemically linking antigens to the Stimulon adjuvants.
* Atlantic Pharmaceuticals Inc., of Half Moon Bay, Calif., has received patent No. 5,583,032 which gives Gemini Gene Therapies Inc., a majority-owned private subsidiary of Atlantic, exclusive rights to any chemical compound that combines any antisense oligonucleotides with any activator of RNase-L, as well as the methods for creating such compounds.
* Calgene Inc., of Davis, Calif., received patent No. 5,576,198 covering high level foreign gene expression in plant plastids.
* CEL-SCI Corp., of Alexandria, Va., has received a Japanese patent covering CEL-SCI's immune-boosting drug, Multikine. The patent covers the basic technology for production of Multikine, which is used for testing various cancers.
* Emisphere Technologies Inc., of Hawthorne, N.Y., received a notice of allowance for a patent on its P3 family of carriers. This patent claims over 30 carriers, the combination of the carriers with various protein and other macromolecular drugs and the use of the carriers to promote oral delivery of drugs currently available only by injections.
* Epic Therapeutics Inc., of Norwood, Mass., has received a broad patent No. 5,578,709, "Macromolecular Microparticles and Methods of Productions," covering the water-based production of microspheres for use in the sustained release delivery of proteins, peptides and other pharmaceuticals. The patent protects the company's core technology, ProMaxx microspheres.
* Focal Inc., of Lexington, Mass., received three patents (Nos. 5,567,435; 5,567,440 and 5,573,934) covering its core technologies related to synthetic absorbable surgical sealants. These patents cover materials and methods for adhering gels to biological tissues.
* GelMed Inc., of Bedford, Maine, received patent No. 5,597,810, "Method for Reducing Absorption of Undesired Lipids in the Gastrointestinal Tract," covering the use of Smart Polymers for the management of cholesterol and the reduction of dietary fats.
* Genelabs Technologies Inc., of Redwood City, Calif., has received patent No. 5,578,444 for "Sequence-Directed DNA-Binding Molecules Compositions and Methods." The patent covers therapies in which a small molecule drug will act by binding to a sequence-specific region of a gene and displacing a regulatory protein from its binding site, potentially creating an entirely new field of drugs for the regulation of disease-associated genes.
* Genetic Vectors Inc., of Miami, has received No. 5,593,829 for the company's EpiDNA Picogram Assay product.
* Geron Corp., of Menlo Park, Calif., received two patents, (Nos. 5,583,016, and 5,580,726). No. 5,583,016 relates to the cloning of the RNA component of human telomerase and provides protection for Geron's cancer diagnostic methods and reagents and therapeutic compounds targeting the RNA component for the treatment of cancer. No. 5,580,726 covers Geron's proprietary Enhanced Differential Display technology.
* IDM, of Paris, has received patent No. 5,595,897, "Polylysine Conjugates," covering a family of biochemical transfection agents for ex vivo and in vivo gene therapy.
* ImClone Systems Inc., of New York, received patent No. 5,580,738, covering the human and murine delta-like (DLK) gene.
* ImmunoGen Inc., of Cambridge, Mass., received a notice of allowance on the company's technology for producing mouse antibodies that appear human to the immune system and fully retain their ability to bind tightly to specific molecular targets.`
* MedImmune Inc., of Gaithersburg, Md., has received patent No. 5,582,827 for RespiGam (Respiratory Syncytial Virus Immune Globulin [Human]). The patent covers the material composition of RespiGam.
* Millennium Pharmaceuticals Inc., of Cambridge, Mass. and Nutley, N.J., received a notice of allowance for certain patent claims related to a human gene called "Uncoupling Protein Homologue," which is important in weight modulation.
* Molecular Biosytems Inc., of San Diego, received two patents related to its ultrasound contrast imaging agents which cover encapsulated gas microspheres comprising perfluorocarbon and other gases: No. 5,552,133, "Method of Making the Encapsulated Gas Microspheres Useful as an Ultrasound Imaging Agent"; No. 5,562,893, "Gas-filled Microspheres with Fluorine Containing Shells."
* Myriad Genetics Inc., of Salt Lake City, received patent No. 5,589,584, covering the AGT (Angiotensinogen) gene mutation.
* Neose Technologies Inc., of Horsham, Pa., has received a patent No. 5,583,042, covering the use of 13 different pairs of glycotransferases, enzymes used to configure the building blocks of complex carbohydrates rapidly and accurately.
* Oncogene Science Inc., of Uniondale, N.Y., received patent No. 5,580,722, covering methods of identifying chemicals that transcriptionally modulate the expression of genes associated with cardiovascular diseases.
* Oncor Inc., of Gaithersburg, Md., received patent No. 5,571,678 covering methods using p43 for the detection of breast cancer, patent No. 5,561,041, covering the use of genetic mutations for the detection of lung cancer cells using sputum samples and patent No. 5,593,840, covering its Tri-Amp nucleic acid amplification technology.
* Pharmos Corp., of Alachua, Fla., received a notice of allowance for a new patent covering permanently ionic derivatives of steroid hormones and their antagonists.
* Progenitor Inc., of Columbus, Ohio, received patent No. 5,591,601 covering its T7T7 nonviral gene delivery system and methods for using the T7T7 system to introduce genes of interest into host cells.
* Sepracor Inc., of Marlborough, Mass., received patent No. 5,595,997 covering the use of decarboethoxyloratadine for the treatment of allergic rhinitis.
* Sibia Neurosciences Inc., of La Jolla, Calif., received patent No. 5,594,011 on a series of compounds, including its lead compound SIB-1508Y, that modulates nicotinic acetylcholine receptors. The patent provides coverage for the composition of the compounds as well as their use for treating Parkinson's disease.
* Texas Biotechnology Corp., of Houston, has received two patents, No. 5,591,761 and No. 5,594,021, which relate to the company's new class of small molecule endothelin-A receptor antagonists, including its lead compound, TBC 11251.
* Tropix, of Bedford, Mass., received a patent granting exclusive rights to new reagent technology that provides the high-sensitivity detection required for new methods of screening pharmaceutical compounds and for early detection of certain cancers and other human diseases. The patent covers a Tropix compound called CDP-Star and related reagents that enable a 10-fold improvement in signal intensity with rapid signal generation properties.
* Tularik Inc., of South San Francisco, has received two patents: No. 5,585,239, covering novel screening assays to identify specific inhibitors of herpes simplex virus and No. 5,591,825 covering signal transducer and activator of transcription 6, a protein which plays a key role in activating the immune response and related drug discovery screening methodology.
* Vical Inc., of San Diego, Calif., has received patent No. 5,580,859 covering the company's technology for direct intramuscular injection of "naked" DNA sequences to cause production of specific proteins intended to prevent or treat diseases and patent No. 5,589,466 covering its method of immunization through direct injection of DNA sequences into muscle or skin.
* Visible Genetics Inc., of Toronto, has received notices of allowance for three patents covering the company's MicroCel disposable DNA sequencing cassette. The MicroCel is a key component of Visible Genetics' Open Gene DNA sequencing system.
* Vyrex Corp., of La Jolla, Calif., received a notice of allowance on its key CD-Tagging technology, a system for the discovering of genes, their proteins and corresponding functions.